Learn More

This week's Fierce Biotech is brought to you by Elephas.

Trouble viewing? Click here.

Faster decisions with the Cybrid™ platform

Cybrid™ is a revolutionary live tumor ex vivo platform that offers biopharma companies the ability to characterize response to oncology immunotherapies rapidly and reliably.

Maintain tumor integrity, improve translatability

The Cybrid™ platform generates live tumor fragments (LTFs)™ directly from a tumor. The process conserves the native tumor microenvironment (TME) and architecture—including fully intact immune and support cells/structures, allowing for improved translatability and de-risking of drug development.

Get rapid results

In as little as 2 weeks of the study start date, we can offer results of the impact of your investigational agent on a tumor and its immune cells.

Experience easy access

A cloud-based portal, CybridView™ offers frictionless access to results and data from studies run through the Cybrid™ platform.

A breadth of outputs available across the development continuum

With Cybrid™ we can offer support at every stage of development with a range of critical outputs. These include:
  • Secretome profiling
  • Cellular markers via flow cytometry
  • Transcriptome analysis
  • Advanced 3D imaging
Learn more about how our biopharma services can help accelerate your oncology immunotherapy development process.








elephas.com

Follow us on   

©2023 Elephas - All rights reserved

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.


You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017